{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:37:32Z","timestamp":1791632252566,"version":"4.3.4"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The current study evaluated the association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and substance use disorders (SUD) in type 2 diabetes and obesity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective nested case-control study using the All of Us Research Program data. Cases were defined as diabetes\/obese individuals with a new diagnosis of alcohol use disorder (AUD), opioid use disorder (OUD), nicotine use disorder (NUD), or cocaine use disorder (CUD). Control participants were drawn from individuals with diabetes or obesity who had no documented history of SUD. Conditional logistic regression was performed to estimate the association between SUD and GLP-1 RA exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included a total of 22,652 participants in the AUD group, 13,226 in the OUD group, 42,320 in the NUD group, and 9,296 in the CUD group; each group comprised both cases and matched control participants. GLP-1 RA use was associated with a 74% reduction in the odds of AUD (odds ratio [OR] = 0.26; 95% confidence interval [CI]: 0.20\u20130.34), a 69% reduction in the odds of OUD (\n                      <jats:italic>OR<\/jats:italic>\n                      = 0.31; 95% CI: 0.23\u20130.42), a 68% reduction in the odds of NUD (\n                      <jats:italic>OR<\/jats:italic>\n                      = 0.32; 95% CI: 0.27\u20130.39), a 75% reduction in the odds of CUD (\n                      <jats:italic>OR<\/jats:italic>\n                      = 0.25; 95% CI: 0.16\u20130.40), and 75% lower odds of any SUD compared with non-users participants (OR = 0.25, 95% CI 0.22\u20130.30).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GLP-1 RA use was consistently associated with lower odds of developing SUDs among individuals with type 2 diabetes or obesity. These findings suggest potential for GLP-1 RAs to help mitigate SUD in these populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1766770","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T06:41:45Z","timestamp":1773124905000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Association between GLP-1 receptor agonist use and substance use disorders among individuals with type 2 diabetes or obesity: a nested case-control study in the All of Us research program"],"prefix":"10.3389","volume":"17","author":[{"given":"Tadesse M.","family":"Abegaz","sequence":"first","affiliation":[{"name":"School of Pharmacy, University of Texas at El Paso","place":["El Paso, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muktar","family":"Ahmed","sequence":"additional","affiliation":[{"name":"College of Medicine and Public Health, Flinders University","place":["Adelaide, SA, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshaya Srikanth","family":"Bhagavathula","sequence":"additional","affiliation":[{"name":"Department of Public Health, College of Health and Human Services, North Dakota State University","place":["Fargo, ND, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Frietze","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Texas at El Paso","place":["El Paso, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","year":"2020","journal-title":"The Lancet."},{"key":"B2","volume-title":"Global status report on alcohol and health and treatment of substance use disorders","year":"2024"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.0242","article-title":"Assessment of annual cost of substance use disorder in US hospitals","volume":"4","author":"Peterson","year":"2021","journal-title":"JAMA Network Open"},{"key":"B4","doi-asserted-by":"publisher","first-page":"209244","DOI":"10.1016\/j.josat.2023.209244","article-title":"Determinants and prevalence of relapse among patients with substance use disorder in a rural population: A retrospective observational study","volume":"157","author":"Suwanchatchai","year":"2024","journal-title":"J Subst Use Addict Treat"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7176.130960","article-title":"Evidence based psychosocial interventions in substance use","volume":"36","author":"Jhanjee","year":"2014","journal-title":"Indian J psychol Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","article-title":"CDC clinical practice guideline for prescribing opioids for pain \u2014 United states, 2022","volume":"71","author":"Dowell","year":"2022","journal-title":"MMWR Recomm Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cger.2021.07.011","article-title":"Prevention strategies of alcohol and substance use disorders in older adults","volume":"38","author":"El Hayek","year":"2022","journal-title":"Clin Geriatr Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/09637214211026984","article-title":"The profound heterogeneity of substance use disorders: Implications for treatment development","volume":"30","author":"Carroll","year":"2021","journal-title":"Curr Dir Psychol Sci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"11782218221118462","DOI":"10.1177\/11782218221118462","article-title":"Barriers and facilitators to substance use disorder treatment: An overview of systematic reviews","volume":"16","author":"Farhoudian","year":"2022","journal-title":"Subst abuse: Res Treat"},{"key":"B10","doi-asserted-by":"publisher","first-page":"108779","DOI":"10.1016\/j.jsat.2022.108779","article-title":"Accessibility of substance use treatment: A qualitative study from the non-service users\u2019 perspective","volume":"141","author":"Caris","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"B11","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1186\/s12913-022-08272-z","article-title":"Drug repurposing: a systematic review on root causes, barriers and facilitators","volume":"22","author":"Krishnamurthy","year":"2022","journal-title":"BMC Health Serv Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes\u2013state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"B13","doi-asserted-by":"publisher","first-page":"107312","DOI":"10.1016\/j.phrs.2024.107312","article-title":"IUPHAR review - Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target","volume":"207","author":"Bruns Vi","year":"2024","journal-title":"Pharmacol Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-3874-y","article-title":"GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial","volume":"59","author":"Farr","year":"2016","journal-title":"Diabetologia."},{"key":"B15","doi-asserted-by":"publisher","first-page":"14899","DOI":"10.3390\/ijms232314899","article-title":"Glucagon-like peptide-1 receptor in the human hypothalamus is associated with body mass index and colocalizes with the anorexigenic neuropeptide nucleobindin-2\/nesfatin-1","volume":"23","author":"Psilopanagioti","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2019.03.029","article-title":"The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: a systematic review","volume":"206","author":"Brunchmann","year":"2019","journal-title":"Physiol behavior."},{"key":"B17","doi-asserted-by":"publisher","first-page":"104772","DOI":"10.1016\/j.neuint.2020.104772","article-title":"Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent","volume":"138","author":"Jensen","year":"2020","journal-title":"Neurochemistry Int"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12295","article-title":"The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents","volume":"21","author":"Vallof","year":"2016","journal-title":"Addict Biol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing semaglutide and liraglutide for alcohol use disorder","volume":"82","author":"Lahteenvuo","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e072707","DOI":"10.1136\/bmjopen-2023-072707","article-title":"Exenatide as an adjunct to nicotine patch for smoking cessation and prevention of postcessation weight gain among treatment-seeking smokers with pre-diabetes and\/or overweight: study protocol for a randomised, placebo-controlled clinical trial","volume":"13","author":"Yammine","year":"2023","journal-title":"BMJ Open"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.170419","article-title":"Effects of dulaglutide on alcohol consumption during smoking cessation","volume":"8","author":"Probst","year":"2023","journal-title":"JCI Insight"},{"key":"B22","doi-asserted-by":"publisher","first-page":"101865","DOI":"10.1016\/j.eclinm.2023.101865","article-title":"Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial","volume":"57","author":"Lengsfeld","year":"2023","journal-title":"EClinicalMedicine."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15677","article-title":"The role of glucagon-like peptide 1 (GLP-1) in addictive disorders","volume":"179","author":"Klausen","year":"2022","journal-title":"Br J Pharmacol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"108614","DOI":"10.1016\/j.drugalcdep.2021.108614","article-title":"Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder","volume":"221","author":"Angarita","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr1809937","article-title":"The \u201cAll of Us\u201d research program","volume":"381","year":"2019","journal-title":"New Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3390\/medsci13030136","article-title":"Mechanisms of GLP-1 in modulating craving and addiction: neurobiological and translational insights","volume":"13","author":"Amorim Moreira Alves","year":"2025","journal-title":"Med Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.3390\/ijms26115338","article-title":"GLP-1 analogues in the neurobiology of addiction: translational insights and therapeutic perspectives","volume":"26","author":"Marquez-Meneses","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"Von Elm","year":"2007","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.23332","article-title":"Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes","volume":"30","author":"Gleason","year":"2024","journal-title":"J Managed Care Specialty Pharmacy."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1097\/ADM.0000000000001575","article-title":"Trends in newly filled GLP-1 receptor agonist prescriptions for US patients with versus without comorbid alcohol use disorder, 2016\u20132024","volume":"10","author":"Wallach","year":"2024","journal-title":"J Addict Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1431292","article-title":"Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists","volume":"15","author":"Liu","year":"2024","journal-title":"Front Endocrinology."},{"key":"B32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.physbeh.2019.03.026","article-title":"Central GLP-1 receptors: Novel molecular targets for cocaine use disorder","volume":"206","author":"Hernandez","year":"2019","journal-title":"Physiol behavior."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.108036","article-title":"Psychotropic effects of GLP-1R agonists","volume":"108036","author":"Bucciarelli","year":"2025","journal-title":"Pharmacol Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2013.00181","article-title":"The central GLP-1: implications for food and drug reward","volume":"7","author":"Skibicka","year":"2013","journal-title":"Front Neurosci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-weekly semaglutide in adults with alcohol use disorder: A randomized clinical trial","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1766770\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T06:41:46Z","timestamp":1773124906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1766770\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":35,"alternative-id":["10.3389\/fpsyt.2026.1766770"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1766770","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"article-number":"1766770"}}